相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutational analysis of breast cancer: Guiding personalized treatments
Matthew J. Ellis
BREAST (2013)
Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy
Kun Wang et al.
TUMOR BIOLOGY (2013)
Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer
Maria T. Baquero et al.
CANCER (2012)
Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies
S. Murray et al.
CANCER TREATMENT REVIEWS (2012)
Prevalence and correlates of major depressive disorder in breast cancer survivors in Shanghai, China
Jianyin Qiu et al.
PSYCHO-ONCOLOGY (2012)
Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients
Ying-Yi Qin et al.
PLOS ONE (2011)
BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy
Charles Dumontet et al.
CLINICAL CANCER RESEARCH (2010)
Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells
Tatiana Spicakova et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
Hirokuni Ikeda et al.
BREAST CANCER RESEARCH (2010)
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
George Pentheroudakis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Lajos Pusztai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recurrence pattern and prognosis in low-risk breast cancer patients - Data from the DBCG 89-A programme
Peer Christiansen et al.
ACTA ONCOLOGICA (2008)
Taxanes, microtubules and chemoresistant breast cancer
Barbara T. McGrogan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2008)
Taxanes as primary chemotherapy for early breast cancer -: Meta-analysis of randomized trials
Federica Cuppone et al.
CANCER (2008)
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
Martine J. Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2007)
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
C. Mazouni et al.
ANNALS OF ONCOLOGY (2007)
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2007)
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial:: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
A. Rody et al.
BREAST (2007)
Targeting the microtubules in breast cancer beyond taxanes: The epothilones
Javier Cortes et al.
ONCOLOGIST (2007)
Predictive factors for response to docetaxel in human breast cancers
Shinzaburo Noguchi
CANCER SCIENCE (2006)
Microtubule associated protein (MAP)-Tau - A novel mediator of paclitaxel sensitivity in vitro and in vivo
P Wagner et al.
CELL CYCLE (2005)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
EP Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol
S Kar et al.
EMBO JOURNAL (2003)
Predicting the clinical status of human breast cancer by using gene expression profiles
M West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
